PAG
APLS

Private Advisor Group’s Apellis Pharmaceuticals APLS Stock Holding History

Private Advisor Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-73,232
Closed -$3.31M – 1925
2022
Q2 		$3.31M Sell
73,232
-108
-0.1% -$4.92K 0.03% 548
2022
Q1 		$3.73M Buy
73,340
+98
+0.1% +$4.33K 0.03% 553
2021
Q4 		$3.46M Sell
73,242
-72,626
-50% -$2.86M 0.03% 593
2021
Q3 		$4.81M Buy
145,868
+74,673
+105% +$4.2M 0.03% 535
2021
Q2 		$4.5M Buy
71,195
+68
+0.1% +$3.51K 0.04% 440
2021
Q1 		$3.05M Buy
71,127
+37
+0.1% +$1.75K 0.03% 546
2020
Q4 		$4.07M Buy
71,090
+565
+0.8% +$23.9K 0.04% 398
2020
Q3 		$2.3M Sell
70,525
-956
-1% -$28.6K 0.03% 513
2020
Q2 		$2.33M Buy
71,481
+85
+0.1% +$2.73K 0.03% 483
2020
Q1 		$1.91M Sell
71,396
-2,387
-3% -$84.7K 0.04% 456
2019
Q4 		$2.26M Sell
73,783
-14,096
-16% -$390K 0.04% 489
2019
Q3 		$2.21M Buy
87,879
+45,229
+106% +$1.24M 0.03% 514
2019
Q2 		$1.08M Buy
+42,650
New +$868K 0.02% 710
2019
Q1 		– Sell
-14,150
Closed -$187K – 1540
2018
Q4 		$187K Buy
+14,150
New +$217K ﹤0.01% 1222

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Private Advisor Group's APLS Position: Q3 2022 in Review

Private Advisor Group sold out of Apellis Pharmaceuticals (APLS) in Q3 2022, closing a stake of 73,232 shares — an estimated $3.31M sold.

Private Advisor Group first reported a position in APLS in Q4 2018 and held it in 14 quarters. The position peaked at $4.81M in Q3 2021. 250 funds tracked by Wall St. Rank hold APLS as of Q3 2022.

  • Private Advisor Group reported no remaining Apellis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Private Advisor Group sold 73,232 Apellis Pharmaceuticals shares in Q3 2022, an estimated $3.31M.
  • Private Advisor Group first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 14 quarters.
  • Private Advisor Group's Apellis Pharmaceuticals position peaked at $4.81M in Q3 2021.
  • 250 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2022.

Based on Private Advisor Group's 13F filing for Q3 2022, filed 14 Oct 2022.